Rapport Therapeutics, Inc. (RAPP) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$27.57

From 52W high−45.52%

Volume299929.00

Market cap$1.37B

P/E (TTM)—

P/S (TTM)68.6x

Div yield—

Key dataOct 19, 2026

Open

$27.57

From 52W high

−45.52%

Volume

299929.00

Market cap

$1.37B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.4x

P/E (TTM)

—

RSI (14)

28.4

MomentumView details →

1D Return

+3.74%

YTD Return

−6.72%

SummaryUpdated Jun 1, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts. The company was originally incorporated as Precision Neuroscience NewCo, Inc. before changing its name in October 2022. Rapport focuses on discovering and developing small molecule medicines to treat central nervous system disorders, representing a relatively young entrant in the competitive biotechnology sector with a specialized focus on neurological conditions.

Ask drillr about Rapport Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.4x

EV/Sales

47.3x

P/S (TTM)

68.6x

P/B (TTM)

3.2x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−685.80%

EBITDA Margin

−741.82%

ROE (TTM)

−32.43%

ROA (TTM)

−29.88%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

—

EPS YoY

−87.48%

FCF YoY

−26.42%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+24.34%

EBITDA YoY

−47.20%

MomentumView details →

1D Return

+3.74%

YTD Return

−6.72%

1Y Return

+7.08%

RSI (14)

28.4

vs 50D SMA

−30.50%

vs 200D SMA

−20.84%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

15.72x

Quick Ratio

15.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.19

EPS Surprise

−6.25%

Beats (12Q)

6/12

Next Q EPS Est

−$1.19

Avg Surprise (4Q)

3.99%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

20.00M

Net Income (TTM)

−137.16M

Op. CF (TTM)

−96.68M

Next earningsNov 5, 2026 →

Latest newsMore news →

Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.76d ago

Similar companies

Ocular Therapeutix, Inc.OCUL Eton Pharmaceuticals, Inc.ETON Tyra Biosciences, Inc.TYRA Inhibrx Biosciences, Inc.INBX ORIC Pharmaceuticals, Inc.ORIC ASCENTAGE PHARMA GROUP INTERNATIONALAAPG Find similar companies →

Latest newsMore news →

Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.76d ago